OBD to present at PMWC 2026

Oxford BioDynamics PLC

03 March 2026

 

Oxford BioDynamics Plc

("OBD" or the "Company" and, together with its subsidiaries, the "Group")

OBD to present at PMWC 2026

Oxford, UK - 3 March 2026 - Oxford BioDynamics Plc (AIM: OBD, the Company), a precision clinical diagnostics company bringing specific and sensitive tests to the practice of medicine based on its EpiSwitch® 3D genomics platform, announces a presentation by its Chief Data Officer Dr Ewan Hunter in the AI and Data Sciences Showcase at Precision Medicine World Conference (PMWC) 2026 in Silicon Valley.

Dr Hunter's presentation, in Showcase Track S1, 11.30am - 12.00pm on 4 March, will be titled "Unfolding the Genome's "Natural Intelligence" with EpiSwitch Orion". Ewan will introduce the Group's newly-launched EpiSwitch Orion platform, explaining how it can be used to turn static DNA information into actionable insights for targeted therapies.

About EpiSwitch Orion

EpiSwitch® Orion is a high-resolution 3D-genomic tool that turns static DNA data into real-time clinical insights. While most tests only look at the protein-coding regions of a person's DNA, Orion analyzes the 98% of the genome often called "dark matter". This dark matter is a critical "control system" that acts like a wiring diagram for our genes. By finding changes in specific EpiSwitch anchor sites within these regions, Orion reveals how the genome's physical structure turns genes on or off. This allows it to bridge the gap between standard Next-Generation Sequencing (NGS) or Genome-Wide Association Studies (GWAS) and the actual functional state of a disease or drug response.

The platform is powered by the EpiSwitch Knowledgebase, the world's largest 3D genomics knowledge graph, which uses Artificial Intelligence (AI) to link over 15 million high-confidence genomic interactions to clinical action. By decoding the "wiring problems" that lead to illness, Orion helps pharmaceutical, biotech, and academic partners group patients more accurately, improve treatments and speed up the delivery of precision medicine for cancer, autoimmune diseases and neurological conditions.

About PMWC 2026

Known as the "Davos of Precision Medicine", PMWC is the largest annual conference dedicated to precision medicine. Its mission is to bring together recognised leaders, top global researchers and medical professionals, and innovators across the healthcare and biotechnology sectors to showcase practical content that helps close the knowledge gap between different sectors, thereby catalyzing cross-functional fertilization and collaboration in an effort to accelerate the development and spread of precision medicine.

This year's conference will feature contributions from many prominent leaders and innovators, including Greg Brockman (Co-founder & President, OpenAI), Judy Faulkner (Founder & CEO, Epic), Vinod Khosla (Founder, Khosla Ventures), Priscilla Chan (Co-founder, Biohub), Steve Wozniak (Co-founder, Apple) and Nobel Laureates Mary Brunkow and W.E. Moerner.

-Ends-

For further details please contact:

Oxford BioDynamics Plc	Tel: [phone]
Iain Ross Executive Chairman Paul Stockdale, CFO
Singer Capital Markets - Nominated Adviser and Broker	Tel: [phone]
Phil Davies / Anastassiya Eley
OAK Securities - Joint Broker	Tel: [phone]
Matthew Clarke / Tim Dainton / Calvin Man
Camarco - Financial PR	Tel: [phone]
Marc Cohen / Tilly Butcher / Fergus Young	[e-mail]

Notes to Editors

About Oxford BioDynamics Plc

Oxford BioDynamics Plc (AIM: OBD) is an international biotechnology company, advancing personalized healthcare by developing and commercializing precision clinical diagnostic tests for life-changing diseases.

Currently, OBD has two commercially available products: the EpiSwitch® PSE (EpiSwitch Prostate Screening test) and EpiSwitch® CiRT (Checkpoint Inhibitor Response Test) blood tests. PSE boosts the predictive accuracy of a PSA test from 55% to 94% when testing the presence or absence of prostate cancer. CiRT is a highly accurate (85%) predictive response test to immuno-oncology checkpoint inhibitor treatments.

The tests are based on OBD's proprietary 3D genomic biomarker technology, the EpiSwitch® platform, which enables screening, evaluation, validation and monitoring of biomarkers to diagnose patients or determine how individuals might respond to a disease or treatment.

EpiSwitch® Orion is a high-resolution 3D-genomic tool that turns static DNA data into real-time clinical insights by analyzing both coding and non-coding regions for changes in specific anchor sites. This allows it to bridge the gap between standard Next-Generation Sequencing (NGS) or Genome-Wide Association Studies (GWAS) and the actual state of a disease or drug response in both blood and tissue samples in multiple organisms. The platform is powered by the EpiSwitch® Knowledgebase, the world's largest 3D genomics knowledge graph, which uses Artificial Intelligence (AI) to link over 15 million genomic interactions to clinical action.

OBD's clinical smart tests have the potential to be used across a broader range of indications, and new tests are being developed in the areas of oncology, neurology, inflammation, hepatology and animal health.

The Group's headquarters and UK laboratories are in Oxford, UK. Its US operations and clinical laboratory are in Maryland, USA, along with a reference laboratory in Penang, Malaysia.

OBD is listed on the London Stock Exchange's AIM (LSE: OBD). For more information, please visit the Company's website, www.oxfordbiodynamics.com,  X (@OxBioDynamics) or LinkedIn.

 

END